Business & Economy · 21 views
Insilico Medicine, SK Biopharmaceuticals strike $2.5B AI drug discovery deal targeting neuroimmune therapies
Insilico Medicine, the Hong Kong–listed AI drug discovery company, has signed a partnership with Korea’s SK Biopharmaceuticals to help develop new drugs for neuroimmune conditions in a deal valued at more than $2.5 billion.
AI Summary
Insilico Medicine and SK Biopharmaceuticals have formed a significant partnership in the field of artificial intelligence-driven drug discovery. This collaboration aims to develop neuroimmune therapies, a promising area of research with potential applications in treating various neurological disorders.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedCoverage Context
More from Business & Economy
Continue reading recent Business & Economy coverage
- Apple event live updates: Ternus announces iPhone 18 Pro and Pro Max in new colorsContinue reading
- Joseph Rice, Lowcountry Lawyer Who Took On Big Tobacco, Dies at 72Continue reading
- These are the 10 biggest retirement fears — and what you can do about themContinue reading
- Treasury Plans $6 Billion in Debt Repurchases to Battle Rising YieldsContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow